Regulatory B cells in experimental stroke

Hilary A. Seifert, Arthur Vandenbark, Halina Offner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Current treatment options for human stroke are limited mainly to the modestly effective infusion of tissue plasminogen activator (tPA), with additional improvement of functional independence and higher rates of angiographic revascularization observed after mechanical thrombectomy. However, new therapeutic strategies that address post-stroke immune-mediated inflammatory responses are urgently needed. Recent studies in experimental stroke have firmly implicated immune mechanisms in the propagation and partial resolution of central nervous system damage after the ischaemic event. A new-found anti-inflammatory role for regulatory B (Breg) cells in autoimmune diseases sparked interest in these cells as potential immunomodulators in stroke. Subsequent studies identified interleukin-10 as a common regulatory cytokine among all five of the currently recognized Breg cell subsets, several of which can be found in the affected brain hemisphere after induction of experimental stroke in mice. Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.

Original languageEnglish (US)
JournalImmunology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Regulatory B-Lymphocytes
Stroke
Tissue Plasminogen Activator
Thrombectomy
Immunologic Factors
Regulatory T-Lymphocytes
Therapeutics
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Interleukin-10
Stroke Volume
Autoimmune Diseases
B-Lymphocytes
Anti-Inflammatory Agents
Central Nervous System
Cytokines

Keywords

  • B cells
  • Brain
  • Cell therapy
  • Neuroinflammation
  • Regulation/suppression

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Regulatory B cells in experimental stroke. / Seifert, Hilary A.; Vandenbark, Arthur; Offner, Halina.

In: Immunology, 01.01.2018.

Research output: Contribution to journalArticle

@article{d0c2f4cabaef4ec8a6f16a857f0c6078,
title = "Regulatory B cells in experimental stroke",
abstract = "Current treatment options for human stroke are limited mainly to the modestly effective infusion of tissue plasminogen activator (tPA), with additional improvement of functional independence and higher rates of angiographic revascularization observed after mechanical thrombectomy. However, new therapeutic strategies that address post-stroke immune-mediated inflammatory responses are urgently needed. Recent studies in experimental stroke have firmly implicated immune mechanisms in the propagation and partial resolution of central nervous system damage after the ischaemic event. A new-found anti-inflammatory role for regulatory B (Breg) cells in autoimmune diseases sparked interest in these cells as potential immunomodulators in stroke. Subsequent studies identified interleukin-10 as a common regulatory cytokine among all five of the currently recognized Breg cell subsets, several of which can be found in the affected brain hemisphere after induction of experimental stroke in mice. Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.",
keywords = "B cells, Brain, Cell therapy, Neuroinflammation, Regulation/suppression",
author = "Seifert, {Hilary A.} and Arthur Vandenbark and Halina Offner",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/imm.12887",
language = "English (US)",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Regulatory B cells in experimental stroke

AU - Seifert, Hilary A.

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Current treatment options for human stroke are limited mainly to the modestly effective infusion of tissue plasminogen activator (tPA), with additional improvement of functional independence and higher rates of angiographic revascularization observed after mechanical thrombectomy. However, new therapeutic strategies that address post-stroke immune-mediated inflammatory responses are urgently needed. Recent studies in experimental stroke have firmly implicated immune mechanisms in the propagation and partial resolution of central nervous system damage after the ischaemic event. A new-found anti-inflammatory role for regulatory B (Breg) cells in autoimmune diseases sparked interest in these cells as potential immunomodulators in stroke. Subsequent studies identified interleukin-10 as a common regulatory cytokine among all five of the currently recognized Breg cell subsets, several of which can be found in the affected brain hemisphere after induction of experimental stroke in mice. Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.

AB - Current treatment options for human stroke are limited mainly to the modestly effective infusion of tissue plasminogen activator (tPA), with additional improvement of functional independence and higher rates of angiographic revascularization observed after mechanical thrombectomy. However, new therapeutic strategies that address post-stroke immune-mediated inflammatory responses are urgently needed. Recent studies in experimental stroke have firmly implicated immune mechanisms in the propagation and partial resolution of central nervous system damage after the ischaemic event. A new-found anti-inflammatory role for regulatory B (Breg) cells in autoimmune diseases sparked interest in these cells as potential immunomodulators in stroke. Subsequent studies identified interleukin-10 as a common regulatory cytokine among all five of the currently recognized Breg cell subsets, several of which can be found in the affected brain hemisphere after induction of experimental stroke in mice. Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.

KW - B cells

KW - Brain

KW - Cell therapy

KW - Neuroinflammation

KW - Regulation/suppression

UR - http://www.scopus.com/inward/record.url?scp=85041577449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041577449&partnerID=8YFLogxK

U2 - 10.1111/imm.12887

DO - 10.1111/imm.12887

M3 - Article

C2 - 29313944

AN - SCOPUS:85041577449

JO - Immunology

JF - Immunology

SN - 0019-2805

ER -